AARD Aardvark Pharma: Price-to-Projected Revenue Ratio

Aardvark Therapeutics Inc - graphic logo of issuer AARD

Aardvark Therapeutics Inc (AARD) is developing oral anti-obesity treatments that target intestinal receptors to suppress appetite. The forward P/S history confirms market expectations, with the metric currently at . The startup focuses on TAS2R receptors for safe weight loss, however, high R&D costs in the absence of sales are leading to a gradual depletion of existing cash reserves.

Aardvark Therapeutics - AARD Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Aardvark Therapeutics Inc (AARD)

Fundamental company analysis:Aardvark Therapeutics Inc. AARD
Original product of Aardvark Pharma

Since Aardvark Therapeutics Inc (AARD) is in the clinical research stage without commercial revenue, operational scalability of the business remains unattainable. This indicator calculates the ratio of current market capitalization to projected sales, allowing the market to value future cash flows; meanwhile, the forward price-to-sales valuation trend serves as a signal regarding the extent of the premium paid for the potential of the company's R&D assets.

Competitors of Aardvark Therapeutics Inc

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio